Compare ADMA Biologics Inc (ADMA) vs Annaly Capital Management, Inc. (NLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Annaly Capital Management, Inc. — how do they compare? ADMA Biologics Inc trades at $9.87 (market cap $2.22B), while Annaly Capital Management, Inc. trades at $23.27 (market cap $17.44B). The key difference: Annaly Capital Management, Inc. is far larger — about 7.9× ADMA Biologics Inc's market cap, and Annaly Capital Management, Inc. pays a 12.96% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | NLY | |
|---|---|---|
Market Cap | $2.22B | $17.44B |
Sector | Health | Financials |
52-Week High | $20.38 | $24.40 |
52-Week Low | $7.60 | $20.21 |
Enterprise Value | $2.29B | — |
Dividend Yield | — | 12.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.
The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.
NLY trades at $22.91, down 0.56% today, with strong technical momentum showing a bullish moving average signal. The stock demonstrates robust fundamentals with a P/E of 5.59, ROE of 20.66%, and consistent earnings beats in recent quarters. Recent Q2 2026 results exceeded expectations with $0.79 EPS versus $0.75 estimate, supported by growing net interest income and dividend coverage improvements.
Analyst consensus remains positive with a $24.50 price target and 57% buy ratings, though investors should monitor interest rate sensitivity given the REIT's mortgage-focused business model. The 13%+ dividend yield provides income appeal, but funding costs and mortgage market volatility present ongoing risks to book value stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →
